CClinicalTrials.gg
SuspendedNCT03269396Updated Jul 22, 2026

Laryngeal Allograft Transplantation

An interventional study of Larynx Allograft Transplantation in Larynx Stenosis, Larynx Disease and Laryngectomy, sponsored by Mayo Clinic. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

Why this study was suspended
Protocol revision
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this proposed study is to obtain safety and efficacy data on human laryngeal allograft transplantation in an effort to safely use these procedures as a viable reconstructive option for patients with severe laryngeal or laryngotracheal incompetence.

Read the detailed description

Patients with severe laryngeal or laryngotracheal incompetence without other reconstructive options will be considered for cadaveric laryngotracheal transplantation. Data will be collected from 10 patients and will include length of hospital stay, short-term complications, long-term complications, hospital readmission, return trips to the operating room (OR), rejection episodes and severity, swallowing function, ability to have tracheotomy tube decannulated, voice parameters, pulmonary function, development of anti-donor antibodies, and quality of life scores.

02

Conditions studied

  • Larynx Stenosis
  • Larynx Disease
  • Laryngectomy
  • Larynx
  • Larynx Fracture

Browse trials for

Keywords

  • severe laryngotracheal dysfunction
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Potential subjects for this study include patients with severe laryngeal dysfunction or a previous laryngectomy. For the purposes of this study, severe laryngeal dysfunction is defined as the loss of normal laryngeal function resulting in significant dysphonia, dysphagia, or dyspnea.

Inclusion criteria

Inclusion Criteria:

  • Ages 18 years and older
  • Male or Female
  • One of the following:

    • Severe laryngeal dysfunction as described above
    • Laryngeal stenosis
    • 5 years or longer s/p definitive management for head and neck cancer
    • Laryngeal cancer requiring total laryngectomy in a patient already on immunosuppression
    • Low-grade chondrosarcoma requiring total laryngectomy
  • Ability to obtain informed consent from the patient

Exclusion criteria

Exclusion Criteria:

Poor surgical candidacy secondary to poor physical/mental health as determined by a pre-operative medical evaluation

General medical status

  • Pregnancy
  • Any systemic disease which would alter life expectancy

    • Active neoplastic disease, not considered yet to be cured (Exceptional cases will be considered in case by case discussion)Less than 5 years s/p definitive management for cancer
    • Cancer within the last 5 years (Exceptional cases will be considered in case by case discussion)
    • Obesity (Body Mass Index >29 - 30)(Exceptional cases will be considered on a case by case basis)
    • Cachexia (BMI\<18)(Exceptional cases will be considered on a case by case basis) Significant renal dysfunction (Creatinine clearance \< 50 ml/min.)
    • Significant hepatic dysfunction
    • Significant kidney damage
    • Unmanageable infections
    • Unable to participate in preoperative exercise training
    • Unable to be weaned to equal or less than 10 mg/day of steroids
    • Untreatable cardiac disease
    • Active neuromuscular disease
    • History of recurrent aspiration or active, unmanageable Gastro-Esophageal Reflux
    • Patients with active connective tissue diseases (exceptions to be considered in a case by case basis)
    • Patients unable to achieve > 600 feet in a 6 minute walk test (exceptions to be considered in a case by case basis)
    • Patients considered having active immunodeficiency disorders (exceptions to be considered in a case by case basis)
    • Multiple co-morbidities that would make transplantation prohibitively risky
  • Psychosocial parameters

    • Severe mental retardation, psychosis, depression or organic brain syndrome
    • Uncontrolled diabetes mellitus. Once HbA1C \< 7, reevaluate for candidacy.
    • Active substance use within 6 months
    • Active smoking within 6 months
    • Active alcoholism within 6 months
    • Inability to comply with transplant-related management and medical follow-up
    • Any other circumstances that deem the candidate high risk from a psychosocial perspective
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Larynx Allograft Transplantation

    Cadaveric laryngotracheal transplantation

    Procedure: Larynx Allograft Transplantation

Interventions

  • ProcedureLarynx Allograft Transplantation

    This study is a prospective clinical trial designed to assess the efficacy and safety of laryngeal transplantation. A total of 10 patients will be enrolled over a five-year timeframe. Study length is 5 years.

05

What researchers measure

Primary outcomes

  1. Survival of the allograft at the one-year visit.

    Survival of the allograft as indicated by histological rejection grading.

    Time frame: 1 year

Secondary outcomes

  1. Swallowing without aspiration at the one-year visit.

    Time frame: 1 year

  2. Voice Evaluation

    Standard voice evaluation will include voice recordings, acoustic and aerodynamic measurements as compared to baseline measurements.

    Time frame: 1 year

  3. Pulmonary function

    Pulmonary function values within normal range.

    Time frame: 1 year

  4. Ability to have tracheotomy tube decannulated

    Ability to have tracheotomy tube decannulated after successful capping trials.

    Time frame: 1 year

06

Study locations

1 site
  • Mayo Clinic in Arizona
    Phoenix, Arizona 85054, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03269396
Lead sponsor
Mayo Clinic
Responsible party
David G. Lott, M.D. (Consultant-Department of Otolaryngology Head & Neck Surgery/Audiology, Mayo Clinic) — Principal investigator
First posted
Aug 31, 2017
Start date
May 19, 2023
Primary completion
May 2028 (estimated)
Completion
May 2033 (estimated)
Last update
Jul 22, 2026

Study contacts

David G Lott, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion